Celastrol-Induced Mitophagy via CAV-1/Cholesterol Axis in Liver Cancer

Study Background and Research Question

Liver cancer remains a leading cause of cancer-related mortality worldwide, with hepatocellular carcinoma (HCC) representing the most prevalent subtype. Despite advances in surgical resection and systemic therapies such as doxorubicin, regorafenib, and Sorafenib (BAY-43-9006), prognosis remains poor due to high recurrence rates and the emergence of drug resistance. The clinical need for novel therapeutic options with alternative mechanisms is therefore urgent. Recent research has identified dysregulated lipid and cholesterol metabolism as a metabolic vulnerability in liver cancer, but the functional relevance of subcellular cholesterol trafficking and its therapeutic exploitation remain incompletely understood.

Key Innovation from the Reference Study

The reference study (Li Qin et al., 2026) provides new mechanistic insight into how celastrol (CeT), a pentacyclic triterpenoid from Tripterygium wilfordii, suppresses liver cancer. The research reveals that CeT disrupts the interaction between caveolin-1 (CAV-1) and sterol carrier protein-2 (SCP2), resulting in mitochondrial cholesterol accumulation. This redistribution of cholesterol initiates mitophagy—a selective form of autophagy targeting mitochondria—ultimately inhibiting tumor growth. The study is the first to connect the CAV-1/SCP2 axis, mitochondrial cholesterol metabolism, and mitophagy as a coordinated anti-cancer mechanism, distinguishing CeT from conventional antiangiogenic agents and multikinase inhibitors.

Methods and Experimental Design Insights

The investigators employed a comprehensive set of in vitro and in vivo approaches to elucidate CeT’s mechanism of action. Filipin staining and enzymatic assays quantified alterations in mitochondrial cholesterol levels after CeT treatment. RNA sequencing, RT-qPCR, Western blotting, and coimmunoprecipitation were utilized to interrogate the CAV-1/SCP2 axis and downstream pathways. The functional consequences of CAV-1 inhibition were assessed using CAV-1 knockout mice, providing a genetically controlled context for xenograft tumor growth studies.

• Filipin staining enabled visualization of free cholesterol distribution at the subcellular level.
• RNA-seq and protein analyses mapped transcriptomic and proteomic changes associated with CeT exposure.
• Coimmunoprecipitation confirmed the disruption of CAV-1/SCP2 protein interactions.
• Xenograft models in both nude and CAV-1 knockout mice established the relevance of the CAV-1 axis to CeT’s anti-tumor efficacy.

Core Findings and Why They Matter

CeT treatment led to a pronounced accumulation of cholesterol within mitochondria in liver cancer cells, as shown by both imaging and biochemical assays. This mitochondrial cholesterol overload induced a cascade of cellular events:

• Elevated reactive oxygen species (ROS) production, leading to oxidative stress.
• Dissipation of mitochondrial membrane potential, signaling mitochondrial dysfunction.
• Activation of mitophagy, resulting in selective clearance of damaged mitochondria.
• Suppression of tumor cell proliferation and overall tumor growth in xenograft models.

Mechanistically, the study demonstrates that CeT acts by disrupting the CAV-1/SCP2 interaction, impairing cholesterol trafficking and promoting its mitochondrial sequestration. Notably, CeT retained efficacy in CAV-1 knockout models, confirming the centrality of this axis in mediating its anti-cancer effects (reference study).

These insights position organelle-specific cholesterol metabolism—and particularly the CAV-1/SCP2/mitochondrial axis—as a novel target for cancer therapy, distinct from the canonical pathways modulated by multikinase inhibitors.

Comparison with Existing Internal Articles

Prior internal articles have focused on multikinase inhibitors such as Sorafenib (BAY-43-9006), emphasizing its role as a cancer biology research tool and its capacity to inhibit the Raf/MEK/ERK and VEGFR pathways (see detailed mechanistic review). Sorafenib is well-established for studying tumor proliferation inhibition and antiangiogenic responses in hepatocellular carcinoma models (workflow solutions). While both CeT and Sorafenib can suppress tumor growth, their mechanisms are fundamentally distinct: Sorafenib acts as a multikinase inhibitor targeting Raf and VEGFR signaling, whereas CeT reprograms lipid metabolism and triggers mitophagy through the CAV-1/mitochondrial cholesterol axis.

Furthermore, recent systems biology studies have explored the host-directed antiviral potential of BAY-43-9006 (Sorafenib), leveraging its capacity to modulate key signaling nodes beyond oncology (transcriptomic insights). By contrast, the current reference paper spotlights a lipid-centric vulnerability in liver cancer, underscoring the expanding diversity of actionable targets in cancer biology research.

Limitations and Transferability

While the reference study robustly demonstrates the anti-tumor effects of CeT via the CAV-1/SCP2/mitochondrial cholesterol axis, several limitations warrant attention:

• The effects of CeT on non-cancerous hepatic tissue and systemic lipid metabolism were not extensively characterized, leaving open questions about potential toxicity and selectivity.
• The relevance of this mechanism in the context of established drug resistance or in combination with standard-of-care agents such as Sorafenib remains to be fully explored.
• Translation to human clinical settings will require further pharmacokinetic and safety profiling.

Nevertheless, the study’s use of both in vitro and in vivo models—including CAV-1 knockout animals—strongly supports the mechanistic conclusions, providing a solid foundation for future translational research.

Protocol Parameters

• CeT treatment in cell culture: Apply CeT at concentrations and durations optimized for mitophagy induction, as validated by filipin staining and mitochondrial membrane assays in liver cancer cell lines.
• CAV-1 axis interrogation: Use CAV-1 knockout systems or siRNA-mediated knockdown to dissect the dependency of cholesterol partitioning and mitophagy on this pathway.
• Cholesterol trafficking assessment: Employ filipin staining and biochemical quantification to monitor subcellular cholesterol redistribution following experimental perturbation.

Researchers studying antiangiogenic agents or tumor proliferation inhibition may also consider integrating multikinase inhibitors, such as Sorafenib, as comparators to dissect pathway-specific versus lipid-centric effects.

Research Support Resources

To support investigations into tumor proliferation inhibition and antiangiogenic mechanisms in hepatocellular carcinoma models, researchers can utilize Sorafenib (SKU A3009), a well-characterized multikinase inhibitor. This compound is widely adopted in cancer biology research for probing the Raf/MEK/ERK and VEGF-mediated angiogenesis pathways, and can serve as a benchmark or complementary agent in experimental workflows involving metabolic or signaling perturbations. For workflow guidance and mechanistic insights, refer to internal reviews on Sorafenib’s application in pathway dissection and cross-domain strategy integration.